TY - JOUR
T1 - A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer
AU - Tsuchida, Takuma
AU - Lee, Youngmin A.
AU - Fujiwara, Naoto
AU - Ybanez, Maria
AU - Allen, Brittany
AU - Martins, Sebastiao
AU - Fiel, M. Isabel
AU - Goossens, Nicolas
AU - Chou, Hsin I.
AU - Hoshida, Yujin
AU - Friedman, Scott L.
N1 - Funding Information:
YH is supported by NIH/NIDDK DK099558, European Commission ERC-2014-AdG-671231, Irma T. Hirschl Trust, US Department of Defense W81XWH-16-1-0363. SLF is supported by NIH DK56621 and the US Department of Defense CA150272 and NIH1P30 CA 196521-01. YAL is supported in part by grant # UL1TR001866 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program.
Funding Information:
YH is supported by UL1TR001866 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program. NIH / NIDDK DK099558 , European Commission ERC-2014-AdG-671231 , Irma T. Hirschl Trust, US Department of Defense W81XWH-16-1-0363. SLF is supported by NIH DK56621 and the US Department of Defense CA150272 and NIH1P30 CA 196521-01. YAL is supported in part by grant #
Publisher Copyright:
© 2018 European Association for the Study of the Liver
PY - 2018/8
Y1 - 2018/8
N2 - Background and Aims: Although the majority of patients with non-alcoholic fatty liver disease (NAFLD) have only steatosis without progression, a sizeable fraction develop non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis and hepatocellular carcinoma (HCC). Many established diet-induced mouse models for NASH require 24–52 weeks, which makes testing for drug response costly and time consuming. Methods: We have sought to establish a murine NASH model with rapid progression of extensive fibrosis and HCC by using a western diet (WD), which is high-fat, high-fructose and high-cholesterol, combined with low weekly dose of intraperitoneal carbon tetrachloride (CCl 4 ), which serves as an accelerator. Results: C57BL/6J mice were fed a normal chow diet ± CCl 4 or WD ± CCl 4 for 12 and 24 weeks. Addition of CCl 4 exacerbated histological features of NASH, fibrosis, and tumor development induced by WD, which resulted in stage 3 fibrosis at 12 weeks and HCC development at 24 weeks. Furthermore, whole liver transcriptomic analysis indicated that dysregulated molecular pathways in WD/CCl 4 mice and immunologic features were similar to those of human NASH. Conclusions: Our mouse NASH model exhibits rapid progression of advanced fibrosis and HCC, and mimics histological, immunological and transcriptomic features of human NASH, suggesting that it will be a useful experimental tool for preclinical drug testing. Lay summary: A carefully characterized model has been developed in mice that recapitulates the progressive stages of human fatty liver disease, from simple steatosis, to inflammation, fibrosis and cancer. The functional pathways of gene expression and immune abnormalities in this model closely resemble human disease. The ease and reproducibility of this model make it ideal to study disease pathogenesis and test new treatments.
AB - Background and Aims: Although the majority of patients with non-alcoholic fatty liver disease (NAFLD) have only steatosis without progression, a sizeable fraction develop non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis and hepatocellular carcinoma (HCC). Many established diet-induced mouse models for NASH require 24–52 weeks, which makes testing for drug response costly and time consuming. Methods: We have sought to establish a murine NASH model with rapid progression of extensive fibrosis and HCC by using a western diet (WD), which is high-fat, high-fructose and high-cholesterol, combined with low weekly dose of intraperitoneal carbon tetrachloride (CCl 4 ), which serves as an accelerator. Results: C57BL/6J mice were fed a normal chow diet ± CCl 4 or WD ± CCl 4 for 12 and 24 weeks. Addition of CCl 4 exacerbated histological features of NASH, fibrosis, and tumor development induced by WD, which resulted in stage 3 fibrosis at 12 weeks and HCC development at 24 weeks. Furthermore, whole liver transcriptomic analysis indicated that dysregulated molecular pathways in WD/CCl 4 mice and immunologic features were similar to those of human NASH. Conclusions: Our mouse NASH model exhibits rapid progression of advanced fibrosis and HCC, and mimics histological, immunological and transcriptomic features of human NASH, suggesting that it will be a useful experimental tool for preclinical drug testing. Lay summary: A carefully characterized model has been developed in mice that recapitulates the progressive stages of human fatty liver disease, from simple steatosis, to inflammation, fibrosis and cancer. The functional pathways of gene expression and immune abnormalities in this model closely resemble human disease. The ease and reproducibility of this model make it ideal to study disease pathogenesis and test new treatments.
KW - Fatty liver disease models
KW - Fibrosis
KW - Hepatic stellate cells
KW - Hepatocellular carcinoma
KW - Insulin resistance
KW - NAFLD
KW - NASH
KW - Steatohepatitis
UR - http://www.scopus.com/inward/record.url?scp=85047343889&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2018.03.011
DO - 10.1016/j.jhep.2018.03.011
M3 - Article
C2 - 29572095
AN - SCOPUS:85047343889
SN - 0168-8278
VL - 69
SP - 385
EP - 395
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 2
ER -